Академический Документы
Профессиональный Документы
Культура Документы
Industrial Guide
Dr A T Bapuji,
M. Pharm Phd.,
CPD-PK Dept,
Aurobindo pharma ltd,
Hyderabad.
Submitted by
K. SUJATHA
(Reg. No.95501035)
Pharmacology.
Institutional Guide
B. Kishore kumar,
M.Pharm,
Dept. of Pharmacology,
SK University.
Contents
Introduction
Literature review
Aim and objective
Plan of work
Clinical Phase
Bioanalytical phase
Results
Conclusion
References
INTRODUCTION
In
ANDA Submission.
The
generic
drug
companies
can
provide
the
evidence
of
BIOAVAILABILITY:
BIOEQUIVALENCE
Definition: The absence of a significant difference in the rate and extent to
which the active ingredient or active moiety in pharmaceutical equivalents becomes
available at the site of drug action when administered at the same molar dose under
similar conditions in an appropriately designed study.
Three situations
When the proposed dosage form is different from that used in pivotal clinical trails,
When significant changes are made in the manufacture of the marketed formulation
and,
When a new generic formulation is tested against the innovator marketed product
Type 1 diabetes
Type 2 diabetes
Diabetes
mellitus type 1:
TREATMENT
Type
1 Diabetes: Insulin:
insulin in order to survive. Exogenous insulin is used to mimic the normal physiological pattern
of insulin secretion as closely as possible, for each individual patient.
Type
Sulfonylureas:
Meglitinides:
Biguanides:
1st&2nd Generations
Repaglinide,Neteglinide
Metformin,Fenformin
Thiazolidinedions:
-Glycosidase
Rosiglitazone,Pioglitazone
inhibitors: acarbose,miglitol
Drug profile
Glyburide
The
Mechanism
of action:
High affinity receptors for sulfonylureas are present on the k ATP channels in -cell
plasma membranes, and the binding of sulfonylureas paralles their potency in
stimulating insulin release. The drugs reduce the k + permeability of -cells by
blocking kATP channnels, causing depolarisation, ca2+ entry and insulin secretion.
8
Pharmacokinetics
Absorption:
It is
Adverse reactions:
Hypoglycemia
GIT Reactions
Hemotological
Drug
reactions
Cyclosporine, etc.
Effect
milk or not.
10
LITERATURE REVIEW
Florin Albu et al., (2006) determined the glibenclamide in human plasma by liquid chromatography
and atmospheric pressure chemical ionization/MS-MS detection.. Inter-sequence accuracy expressed
as % bias from theoretical concentration values over the concentration interval of 10400 ng/mL fall
within 13.9% and +14.6%. The method was applied for evaluation of the bioequivalence between
two formulations containing 3.5 mg glibenclamide per dose.
B. F. Clarke et al., (2003) conducted the long-term comparative trial of glibenclamide and
chlorpropamide in diet-failed, maturity-onset diabetics: The final blood-glucose and change in
body-weight were similar in patients from both treatment groups still taking the original
sulphonylurea agent 2 years later. Hypoglycmic episodes were more common and severe in
the glibenclamide-treated patients.
11
Aim:
The basic aim of this project was conductance of bioequivalence study, in
accordance with the regulatory guidelines. The conductance of Bioequivalence
study on a test product A, (Glyburide 5mg tablets of Aurobindo Pharma Ltd; India)
and reference product B, (Micronase tablets containing Glyburide 5mg of Pharmacia
&Upjohn; USA)
Objectives:
Compare the rate and extent of absorption of Glyburide tablets (test) of
Aurobindo Pharma Ltd; India with that of Reference tablets (Micronase of
Pharmacia &Upjohn, USA) when given in equal doses of single oral dose
containing 5mg of Glyburide in 14 healthy, adult, male, human subjects under
fasting conditions.
12
Plan of work
Preparation of Protocol
Submit IRB for approval
Registration of the volunteers
Screening
Subject selection (12+2)
Period 1
R
Washout
period
7days
T
Checkout process
Period 2
R
13
Clinical phase
ETHICAL CONSIDERATIONS:
Written
Informed Consent:
ICF is designed as per the ICH-GCP and local regulatory requirements. ICF is conducted in order to get the consent from
the volunteer to participate in the study.
Study Design:
Open label, randomized, two-treatment, two-sequence, two-period, cross-over, single-dose,
comparative oral bioavailability study of Glyburide 5mg tablets in 14 healthy, adult, male, human
subjects, under fasting condition.
14
Registration of volunteers:
registered in the database after they gave the written consent. The following
eligibility assessments were carried out before enrolling any volunteer into
study which include
Screening:
15
Inclusion Criteria:
Body mass index of 18.5 kg/m2 and 24.9 kg/ m2, with
body weight not less than 50 kg.
Exclusion
Criteria:
Sex
Age
Weight
(Yrs)
(Kg)
Height
(cm)
BMI
S(X)/
(kg/m2)
NS
S1
Male
36
56
171
19.15
S(2)
S2
Male
25
58
162
22.10
NS
S3
Male
27
58
160
22.66
NS
S4
Male
22
56
166
20.32
NS
S5
Male
33
72
170
24.91
NS
S6
Male
28
50
160
19.53
NS
S7
Male
22
60
156
24.65
NS
S8
Male
41
64
173
21.38
NS
S9
Male
28
60
165
22.04
NS
S10
Male
22
58
174
19.16
NS
S11
Male
20
52
160
20.31
NS
S12
Male
27
70
172
23.66
NS
S13
Male
28
54
163
20.3
NS
S14
Male
24
66
165
24.2
NS
17
Randomization scheme
Subject
No
Sequence
Period I
Period II
TR
RT
TR
RT
RT
TR
TR
RT
10
TR
11
RT
12
TR
13
RT
14
TR
18
Dietary plan:
Subjects were fasted overnight (at least 10 hours) before dosing and minimum of 4 hours
thereafter. Post dose meal on Day 1(Dosing Day) consisting of approx. 2200 Kcal as per the meal
plan provided by dietician was provided.
Sampling schedules:
The venous blood samples were withdrawn pre-dose and at 0.5, 1.0, 2.0,
3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0 and 48.0 hours postdose.
Blood loss:
For each subject the total number of blood draws were 34 (17x2 for 2
periods). The total volume of blood withdrawn was 255 mL.
19
Sampling
of Adverse Events:
Subject
Perio
Adverse
Action
Number
Events
Taken
S1
Mild
hypoglycemia
S8
Nausea
S11
Nausea
S12
II
Mild
Recovered
without
Medication
hypoglycemia
20
Study Conduct:
All the 14 subjects were dosed and 13 subjects completed the
study. Subject No. S7 was tested positive for Benzodiazepines
during the day of check-in of Period-II. Hence, that subject was
withdrawn from the study.
SAFETY ASSESSMENT:
Safety assessment was carried out at the time of screening and during the
course of study by conducting medical examination, recording vital signs and
adverse event monitoring.
21
Bioanalytical phase
Before beginning of the analysis for a molecule a method for its analysis has to be
developed.
Materials
and methods:
Glyburide
Molecular Weight
494.003520 [g/mol]
2.08 ng/mL
Calibration Range
Internal Standard
Glimepiride
Instrument Method
LC/MS/MS
22
Results
Statistical analysis was performed on plasma
glyburide using the SAS system version 9.1.3..
80
T
60
40
20
0
0
12
16
20
24
28
32
36
40
44
48
Time (hr)
23
Semilog Mean plasma Concentration Vs Time profile of Glyburide 5 mg tablets under fasting conditions
1000.0
100.0
R
T
10.0
1.0
0.1
0
12
16
20
24
28
32
36
40
44
48
Time (hr)
24
Subj
ect
1
2
3
4
5
6
8
9
10
11
12
13
14
Sequ
ence
TR
RT
TR
RT
RT
TR
TR
RT
TR
RT
TR
RT
TR
N
Mean
SD
Min
Median
Max
CV%
Tmax
Cmax
AUClast
Treatment
Treatment
Treatment
R
10.00
4.00
5.00
6.00
8.00
12.00
8.00
6.00
6.00
4.00
6.00
6.00
8.00
13
6.85
2.304
4.00
6.00
12.00
33.65
T
4.50
6.00
6.00
8.00
8.00
8.00
8.00
6.00
4.00
8.00
6.00
6.00
6.00
13
6.50
1.384
4.00
6.00
8.00
21.30
R
68.31
127.86
158.28
121.38
107.26
164.70
299.94
171.07
129.76
142.35
134.31
203.83
127.90
13
150.53
55.615
68.31
134.31
299.94
36.95
T
94.60
121.07
218.51
115.00
89.44
153.30
346.51
89.02
158.33
115.12
186.97
195.79
96.93
13
152.35
72.647
89.02
121.07
346.51
47.68
R
761.03
1129.53
1531.50
598.17
836.05
1199.93
4972.65
897.42
998.61
750.37
645.87
1546.34
926.37
13
1291.83
1146.066
598.17
926.37
4972.65
88.72
T
747.34
1487.59
1658.26
826.77
873.23
1130.21
4959.50
832.74
1056.10
819.85
699.51
1399.83
780.53
13
1328.57
1134.092
699.51
873.23
4959.50
85.36
25
Comparative evaluation of PK
parameters
AUCINF_obs
Treatment
Lambda_z
Treatment
HL_Lambda_z
Treatment
Subj
ect
Sequ
ence
TR
822.12
825.54
0.0966
0.0509
7.18
13.62
2
3
4
5
6
8
9
10
11
12
13
14
RT
TR
RT
RT
TR
TR
RT
TR
RT
TR
RT
TR
N
1156.34
1617.44
611.89
863.59
1217.97
5614.36
925.03
1035.23
783.14
658.38
1594.83
954.54
13
1526.67
1707.06
840.12
895.52
1170.73
5109.14
855.86
1071.80
842.04
711.03
1420.89
794.64
13
0.1544
0.0524
0.1727
0.1227
0.1397
0.0582
0.1955
0.1213
0.1401
0.2198
0.0870
0.2041
13
0.1121
0.0826
0.2337
0.1306
0.1959
0.0780
0.1969
0.1414
0.2041
0.2404
0.1092
0.2267
13
4.49
13.24
4.01
5.65
4.96
11.92
3.54
5.72
4.95
3.15
7.96
3.40
13
6.18
8.39
2.97
5.31
3.54
8.89
3.52
4.90
3.40
2.88
6.35
3.06
13
Mean
1373.45
1367.00
0.1357
0.1540
6.17
5.62
1312.117
611.89
1167.658
711.03
0.05348
0.0524
0.06531
0.0509
3.186
3.15
3.144
2.88
954.54
895.52
0.1397
0.1414
4.96
4.90
Max
5614.36
5109.14
0.2198
0.2404
13.24
13.62
CV%
95.53
85.42
39.40
42.40
51.66
55.98
SD
Min
Median
26
AUC0-t
AUC0-inf
(ng/mL)
(hr*ng/mL)
(hr*ng/mL)
Test Formulation
138.09
1106.60
1138.78
Reference
Formulation
142.32
1059.20
1102.91
97.03
104.47
103.25
Parameter
Lntransformed Data
Geometric Mean
90% Confidence
86.37 - 109.00 97.64 - 111.79 96.37 - 110.63
Interval
Intra subject CV
(%)
16.63
9.63
9.82
Power (%)
93.62
99.92
99.90
27
Conclusion
All
The
Hence
References
Shein-Chung
Chow, Jen Pei Liu. Design and Analysis of BA & BE Studies, Marcel
Dekker, 2nd Ed. Vol 133:1-30.
Shargel, L.; Yu, A.B. 1999. Applied Biopharmaceutics & pharmacokinetics 4th
Ed. New York: McGraw-Hill.
Food and drug administration (FDA), Guidance for Industry: Statistical
approaches to establishing bioequivalence 2001.
Brahmankar D.M and Sunil B. Jaiswal, Biopharmaceutics and Pharmacokinetics,
A treatise published by M.K Jain for Wallabh Prakashan, printed by goyal offset
works, Delhi 110088, first edition, page 282-305.
Center for Drug Evaluation and Research. "Guidance for Industry: Bioavailability
and Bioequivalence Studies for Orally Administered Drug Products General
Considerations". United States Food and Drug Administration, 2003:1-23.
Code of Federal Regulations Title 21--Food and Drugs Chapter I--Food and Drug
Administration, Department of Health and Human Services--Continued Part 320
Bioavailability and Bioequivalence Requirements [Title 21, Volume 5, Parts
300 to 499][Revised as of April 1, 2000][CITE: 21CFR320][Page 186].
Guidelines for Bioavailability and Bioequivalence Studies, Central Drugs
Standard Control Organization, Directorate General of Health Services, Ministry
of Health and Family welfare, Government of India, New Delhi, March 2005; 333.
29
THANK
YOU
31